Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04906434 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor
A Phase 1 study of Advanced Liver Cancer, sponsored by Abbisko Therapeutics Co.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT04906434: Recruiting Phase 1 study of Advanced Liver Cancer, sponsored by Abbisko Therapeutics Co.
NCT04906434 is a Phase 1 study of Advanced Liver Cancer that is actively recruiting participants, run by Abbisko Therapeutics Co. The registered enrollment target is 200 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (233% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04906434, a Phase 1 study of Advanced Liver Cancer, is actively recruiting participants, sponsored by Abbisko Therapeutics Co.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label phase 1 study with an escalation part and an expansion part.
Primary Outcome
Incidence of dose-limiting toxicities (DLTs) in Cycle 1
Conditions Studied
Interventions
- DRUG ABSK-011
Study Locations (20)
Florida
- Mayo Clinic - Jacksonville
- Moffitt Cancer Center - Tampa
Beijing Municipality
- Beijing Tsinghua Changgung Hospital - Beijing
- The Fifth Medical Center of the General Hospital of the Chinese People's Liberation Army - Beijing
Henan
- First Affiliated Hospital of Henan University of Science and Technology - Luoyang
- Henan Cancer Hospital - Zhengzhou
Hubei
- Hubei Cancer Hospital - Wuhan
- Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology - Wuhan
Arizona
- Mayo Clinic - Phoenix
Minnesota
- Mayo Clinic - Rochester
New York
- Icahn School of Medicine at Mount Sinai - New York
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2020-02-26 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
What NCT04906434 shows while recruiting
NCT04906434 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (233% higher).
The record links to 1 condition, with Advanced Liver Cancer appearing as the primary indexed condition, and to 1 intervention - of which ABSK-011 is the first listed.
NCT04906434 names 20 study sites across 16 states, led by Florida, Beijing Municipality, Henan.
Frequently Asked Questions
What is clinical trial NCT04906434 about?
NCT04906434 is a clinical study titled "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor". This is an open-label phase 1 study with an escalation part and an expansion part.
What is the current status of trial NCT04906434?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2020-02-26. Estimated completion is 2028-12-31.
What conditions does trial NCT04906434 study?
This clinical trial studies the following conditions: Advanced Liver Cancer.
What interventions are being tested in trial NCT04906434?
The interventions under investigation include: ABSK-011 (DRUG).
Who is sponsoring clinical trial NCT04906434?
This trial is sponsored by Abbisko Therapeutics Co, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04906434 being conducted?
This trial has 20 study locations across Arizona, Florida, Minnesota, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04906434's enrollment target sits among peer trials
200 260th of 2000 higher than 1,724 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI